IVX Stock Overview
A clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Invion Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.20 |
| 52 Week High | AU$0.70 |
| 52 Week Low | AU$0.20 |
| Beta | 1.26 |
| 11 Month Change | -20.00% |
| 3 Month Change | -33.33% |
| 1 Year Change | -71.43% |
| 33 Year Change | -88.89% |
| 5 Year Change | -85.71% |
| Change since IPO | -96.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| IVX | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | -16.4% | 0.9% |
| 1Y | -71.4% | 32.3% | 18.4% |
Return vs Industry: IVX underperformed the Australian Pharmaceuticals industry which returned 32.3% over the past year.
Return vs Market: IVX underperformed the Australian Market which returned 18.4% over the past year.
Price Volatility
| IVX volatility | |
|---|---|
| IVX Average Weekly Movement | 30.2% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: IVX's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: IVX's weekly volatility (30%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Thian Chew | www.inviongroup.com |
Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, and solid cancers, such as lung, ovarian, anogenital, and glioblastoma multiforme cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion’s IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer.
Invion Limited Fundamentals Summary
| IVX fundamental statistics | |
|---|---|
| Market cap | AU$14.31m |
| Earnings (TTM) | -AU$5.63m |
| Revenue (TTM) | AU$3.69m |
3.9x
P/S Ratio-2.5x
P/E RatioIs IVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVX income statement (TTM) | |
|---|---|
| Revenue | AU$3.69m |
| Cost of Revenue | AU$2.69m |
| Gross Profit | AU$1.00m |
| Other Expenses | AU$6.63m |
| Earnings | -AU$5.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.083 |
| Gross Margin | 27.16% |
| Net Profit Margin | -152.34% |
| Debt/Equity Ratio | 0% |
How did IVX perform over the long term?
See historical performance and comparison